OXYPERTINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H29N3O2
Molecular Weight	379.4953
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(C=C1OC)C(CCN3CCN(CC3)C4=CC=CC=C4)=C(C)N2

InChI

InChIKey=XCWPUUGSGHNIDZ-UHFFFAOYSA-N

InChI=1S/C23H29N3O2/c1-17-19(20-15-22(27-2)23(28-3)16-21(20)24-17)9-10-25-11-13-26(14-12-25)18-7-5-4-6-8-18/h4-8,15-16,24H,9-14H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C23H29N3O2
Molecular Weight	379.4953
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5322447
Curator's Comment: Description was created based on several sources, including http://imr.sagepub.com/content/1/6/573.full.pdf

Oxypertine (Equipertine, Forit, Integrin, Lanturil, Lotawin, Opertil) is a neuroleptic drug and was originally introduced as a treatment for schizophrenia in the 1960s. Oxypertine is an indole derivative with general properties similar to those of the phenothiazine, chlorpromazine. It has been given by mouth in the treatment of various psychoses including schizophrenia, mania, and disturbed behaviour, and of severe anxiety. Like reserpine and tetrabenazine, oxypertine depletes catecholamines, though not serotonin, possibly underlying its neuroleptic efficacy. The molecular structure is strongly similar to solypertine and milipertine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Adrenergic receptor alpha-1 171 Target ID: CHEMBL1907610 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084	Antagonist 2849	54.0 nM [IC50]
Dopamine receptor 60 Target ID: CHEMBL2093868 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084	Antagonist 2849	210.0 nM [IC50]
Adenylate cyclase 13 Target ID: CHEMBL2095179 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084	Inhibitor 8504
Serotonin receptors 2 Target ID: Serotonin receptors Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084	Antagonist 2849	25.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Tardive dyskinesia 15 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6140973	Primary	Preclinical	Unknown Approved Use Unknown
Schizophrenia 305 Sources: http://en.pharmacodia.com/web/drug/1_10056.html	Primary	Approved 8583	FORIT Approved Use Oxypertine is primarily indicated in conditions like Mania, Psychosis, Schizophrenia.
Psychosis 16 Sources: http://en.pharmacodia.com/web/drug/1_10056.html	Primary	Approved 8583	FORIT Approved Use Oxypertine is primarily indicated in conditions like Mania, Psychosis, Schizophrenia.

AUC

Value	Dose	Co-administered	Analyte	Population
34 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6707118/	25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		1-PHENYLPIPERAZINE plasma	Rattus norvegicus population: HEALTHY age: UNKNOWN sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
560 mg multiple, oral Highest studied dose Dose: 560 mg Route: oral Route: multiple Dose: 560 mg Sources: https://pubmed.ncbi.nlm.nih.gov/5322447/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/5322447/	Sources: https://pubmed.ncbi.nlm.nih.gov/5322447/

PubMed

Title	Date	PubMed
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.	2010-03-03	20209133
Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.	2004-11-26	15519367
Towards pick-and-place assembly of nanostructures.	2004-03	15233090
Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.	2003-12-25	14643514
GAF film dosimetry of a tandem positioned beta-emitting intravascular brachytherapy source train.	2003-06	12852522
The "Haptic Finger"- a new device for monitoring skin condition.	2003-05	12709131
Enhanced separation of filamentous fungi by ultrasonic field: possible usage in repeated batch processes.	2002-08-07	12067525
Effects of sulpiride and oxypertine on the dopaminergic system in the rat striatum.	1992	1351265
Biochemical versus psychopathological action profile of neuroleptics: a comparative study of chlorpromazine and oxypertine in acute psychotic disorders.	1975-05-01	237735

Patents

Sample Use Guides

In Vivo Use Guide

Oxypertine 20 mg given orally as a nocturnal sedative and again on the morning of operation produced relief of anxiety

Route of Administration: Oral

In Vitro Use Guide

Oxypertine inhibited [3H]WB-4101 binding in rat cerebral cortex membranes with IC50 54 nM

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:32:02 GMT 2025` Edited by `admin` on `Wed Apr 02 08:32:02 GMT 2025`
Record UNII	5JGL4G25R7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXYPERTINE

Official Name

English

FORIT

Preferred Name

English

5,6-Dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]indole

Systematic Name

English

WIN 18,501-2

Code

English

WIN-18501-2

Code

English

OXYPERTINE [MART.]

Common Name

English

OXYPERTINE [USAN]

Common Name

English

OXYPERTINE [JAN]

Common Name

English

1H-INDOLE, 5,6-DIMETHOXY-2-METHYL-3-(2-(4-PHENYL-1-PIPERAZINYL)ETHYL)-

Systematic Name

English

OXYPERTINE [MI]

Common Name

English

WIN-185012

Code

English

oxypertine [INN]

Common Name

English

Oxypertine [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN05AE01